2024
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian age
2023
Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases
Upadhyay R, Klamer B, Perlow H, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Mestres-Villanueva M, Healy E, Thomas E, Chakravarti A, Raval R, Lustberg M, Williams N, Palmer J, Beyer S. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases. Cancers 2023, 16: 137. PMID: 38201564, PMCID: PMC10778270, DOI: 10.3390/cancers16010137.Peer-Reviewed Original ResearchIntracranial progression-free survivalProgression-free survivalBreast cancer patientsBrain metastasesOverall survivalYounger patientsCancer patientsRadiation necrosisOlder womenOlder patientsPositive diseaseSystemic therapyMultivariable analysisTreatment patternsBiopsy-proven breast cancer patientsCox proportional hazards regression methodsIncidence of BMOlder breast cancer patientsSingle-institutional retrospective reviewTreatment-related adverse eventsAge groupsBreast cancer brain metastasesMetastatic breast cancer patientsWorse progression-free survivalProportional hazards regression methodsPhase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer
Williams N, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai S, Stover D, Lustberg M, Noonan A, Cherian M, Bystry D, Hill K, Chen M, Phelps M, Grever M, Stephens J, Ramaswamy B, Carson W, Wesolowski R. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer. Therapeutic Advances In Medical Oncology 2023, 15: 17588359231217976. PMID: 38152697, PMCID: PMC10752118, DOI: 10.1177/17588359231217976.Peer-Reviewed Original ResearchAdvanced triple-negative breast cancerTriple-negative breast cancerProgression-free survivalDuration of responseOverall response ratePrior taxane therapyAdverse eventsTaxane therapyCombination therapyBreast cancerMedian DORMedian progression-free survivalNon-hematologic adverse eventsPhase Ib studyPhase Ib trialPhase II doseAcceptable toxicity profileDose-limiting toxicityDrug interaction profileIb trialIntravenous paclitaxelPaclitaxel efficacyExpansion cohortCombination regimenMetastatic disease
2021
Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.
Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.Peer-Reviewed Original ResearchFirst-line endocrine therapyProgression-free survivalInvasive lobular carcinomaMedian progression-free survivalEndocrine therapyMedian overall survivalOverall survivalBreast cancerDuctal cancerLobular cancerEstrogen receptor/progesterone receptorMetastatic invasive lobular carcinomaOhio State University Comprehensive Cancer CenterDistinct clinicopathologic characteristicsInitial endocrine therapyInitiation of chemotherapyYear of diagnosisKaplan-Meier methodMetastatic breast cancerSite of metastasisInvasive breast cancerSingle-institution studyComprehensive cancer centerLine endocrine therapyConcerns of resistance
2019
350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)
Wesolowski R, Brufsky A, Chambers M, Bhattacharya S, Lustberg M, VanDeusen J, Sardesai S, Williams N, Noonan A, Phelps M, Grever M, Stephens J, Carson W, Ramaswamy B. 350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173). Annals Of Oncology 2019, 30: v126. DOI: 10.1093/annonc/mdz242.045.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall response rateNegative breast cancerBreast cancerDay 1Cancer Therapy Evaluation ProgramCycle 1Clinical benefit rateCommon grade 3Dose level 1Dose-expansion studyHigher adverse eventsPhase Ib studySchedule of paclitaxelAcceptable safety profileProgression-free survivalHeat shock protein 90 inhibitorShock protein 90 inhibitorsNational Cancer InstituteEvaluable ptsPaclitaxel hypersensitivityStudy regimenAdverse eventsMethods PatientsSafety profileCLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Boutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.Peer-Reviewed Original ResearchMetastatic invasive lobular carcinomaProgression-free survivalInvasive lobular carcinomaFirst-line treatment groupEndocrine therapyFirst-line treatmentOverall survivalCDK 4/6 inhibitorsMetastatic settingBone metastasesTreatment groupsMedian progression-free survivalOhio State University Comprehensive Cancer CenterInvasive breast cancer casesOnly bone metastasesMedian overall survivalFirst-line therapyWidespread metastatic diseaseKaplan-Meier methodRetrospective chart reviewSingle institution experienceInvasive ductal cancerKaplan-Meier curvesPreferred treatment optionAppropriate clinical context
2018
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.
Saito Y, Li Z, Lustberg M, Grenade C, Wesolowski R. Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. Cancer Treatment And Research Communications 2018, 16: 9-12. PMID: 31299005, DOI: 10.1016/j.ctarc.2018.04.001.Peer-Reviewed Original ResearchNeuroendocrine carcinomaExceptional responseLarge cell neuroendocrine carcinomaEarly phase clinical trialsProgression-free survivalMetastatic prostate cancerCell neuroendocrine carcinomaNumber of malignanciesPrimary human tumorsMechanism of actionCancer cell linesFree survivalCell cycle arrestClinical trialsProstate cancerDNA damaging drugsNovel ATR inhibitorPatientsHuman tumorsM6620Cytotoxic effectsCycle arrestRemarkable responseDamaging drugsClonal evolution
2017
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerDay 1Hormone receptor-positive breast cancerReceptor-positive breast cancerPhase Ib studyPhase II doseProgression-free survivalPositive breast cancerOverall response rateHeat shock protein 90 inhibitorNegative breast cancerCycle 1Shock protein 90 inhibitorsPoor outcomeStandard doseAndrogen receptorHsp90 client proteinsHeat shock protein 90Ib studyResponse durationToxicity profilePaclitaxel resistanceClient proteinsDay 7
2016
Metaplastic progression free survival compared to triple negative breast cancer, a retrospective analysis.
Lustberg M, Luff A, Young G, Layman R, Mrozek E, Reinbolt R, Wesolowski R, Ramaswamy B. Metaplastic progression free survival compared to triple negative breast cancer, a retrospective analysis. Journal Of Clinical Oncology 2016, 34: e12552-e12552. DOI: 10.1200/jco.2016.34.15_suppl.e12552.Peer-Reviewed Original ResearchTriple-negative breast cancerProgression-free survivalNegative breast cancerFree survivalBreast cancerRetrospective analysis
2015
Palbociclib
Mangini N, Wesolowski R, Ramaswamy B, Lustberg M, Berger M. Palbociclib. Annals Of Pharmacotherapy 2015, 49: 1252-1260. PMID: 26324355, PMCID: PMC7331461, DOI: 10.1177/1060028015602273.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCyclin-Dependent KinasesDisease-Free SurvivalEstradiolFemaleFulvestrantHumansLetrozoleNeoplasms, Hormone-DependentNitrilesPiperazinesPyridinesRandomized Controlled Trials as TopicReceptor, ErbB-2TriazolesUnited StatesConceptsProgression-free survivalAdvanced breast cancerInvestigator-assessed median progression-free survivalMedian progression-free survivalPhase III trialsBreast cancerEndocrine therapyIII trialsOncology abstractsHER2-negative advanced breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Negative advanced breast cancerConfirmatory phase III trialClinical Oncology abstractsMedical Oncology abstractsPALOMA-3 trialFirst-line settingPhase II trialGrowth factor receptor 2Drug Administration approvalFactor receptor 2Life-threatening diseaseCyclin-dependent kinase 4Novel small molecule inhibitor
2014
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
Zhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E, Wesolowski R, Carothers S, Puhalla S, Shapiro C, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs 2014, 32: 1285-1294. PMID: 24894652, PMCID: PMC4303337, DOI: 10.1007/s10637-014-0122-5.Peer-Reviewed Original ResearchConceptsProgression-free survivalLeft ventricular ejection fractionClinical benefit rateHER2-positive MBCObjective response rateComplete responsePartial responseBreast cancerStable diseaseFree survivalGrade 3HER2-positive metastatic breast cancerResponse rateAdditional overall survival benefitsMedian progression-free survivalMetastatic breast cancer patientsPositive metastatic breast cancerVascular epithelial growth factorCommon grade 3Cycles of bevacizumabGrade 2 hypertensionMethods Eligible patientsPrior chemotherapy regimensCombination of bevacizumabHand-foot syndrome
2012
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes
Lustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.Peer-Reviewed Original ResearchConceptsObjective response rateMetastatic breast cancerWeekly paclitaxelAnti-tumor activityII trialBreast cancerPhase I/II trialMedian progression-free survivalGrowth factorPhase IMedian overall survivalResultsThirty-one patientsPhase II trialProgression-free survivalDose-limiting toxicityBasic fibroblast growth factorPre-specified criteriaNon-cytotoxic dosesFibroblast growth factorPrior taxaneMetastatic settingUnacceptable toxicityOverall survivalPolypeptide growth factorsSuramin concentrations